Daniel Lewin

2 weeks ago | onlinelibrary.wiley.com | Marta Medina |Daniel Lewin |Hendrik Treede |Sebastian Rojas

Introduction Cardiogenic shock (CS) remains a challenge in cardiovascular medicine with 30-day mortality rates of 40 to 50%1 in patients requiring mechanical circulatory support.2 One therapeutic option for these patients are durable left ventricular assist devices (dLVADs).